Abiraterone approved for clinical use in Scotland

As previously projected, the Scottish Medicines Consortium has now approved the clinical use of abiraterone acetate, making the drug available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after failure of treatment with docetaxel-based chemotherapy throughout the United Kingdom.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: